• Meropenem in Resistance Dynamics: Genomic Insights for Trans

  2026-05-01

  Discover how Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, informs advanced translational research through the lens of carbapenemase gene dynamics. This article uniquely connects genomic resistance data to practical assay decisions, differentiating itself from existing scenario-driven or mechanistic guides.

• nor-Binaltorphimine Dihydrochloride: Decoding KOR Circuits i

  2026-04-30

  Explore the nuanced role of nor-Binaltorphimine dihydrochloride as a κ-opioid receptor antagonist in unraveling pain modulation circuits. This article offers a mechanistic and assay-focused perspective, grounded in recent brain-to-spinal circuit discoveries.

• Triiodothyronine (T3): Powering Translational Metabolic Rese

  2026-04-30

  This thought-leadership article provides translational researchers with a nuanced exploration of Triiodothyronine (T3)—its mechanistic role in adipocyte thermogenesis, strategic value in metabolic disorder research, and best practices for robust experimental design. By synthesizing mechanistic evidence from recent literature with APExBIO’s high-purity T3 product intelligence, the piece offers actionable insights for advancing thyroid hormone signaling pathway studies and elevating research reproducibility.

• In Vivo Detection of Cardiomyocyte Apoptosis Using Annexin V

  2026-04-29

  This study demonstrates the use of labeled recombinant human Annexin V for early and in situ detection of cardiomyocyte death after myocardial ischemia and reperfusion (I/R) in mice. The findings establish Annexin V as a sensitive marker for phosphatidylserine externalization, enabling precise measurement of the time course and therapeutic modulation of apoptosis in cardiac injury.

• Enhanced ECL Chemiluminescent Substrate Detection Kit in Pro

  2026-04-29

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) from APExBIO empowers researchers with ultra-sensitive, low-background western blot detection down to low-picogram levels. Its streamlined, robust protocol and compatibility across imaging platforms set it apart for advanced protein immunodetection and troubleshooting in challenging experimental scenarios.

• IWP-2: Advancing Wnt Pathway Inhibition for Translational Re

  2026-04-28

  Explore how IWP-2, a potent Wnt production inhibitor from APExBIO, is reshaping experimental strategies in cancer research and developmental biology. This article integrates mechanistic insights, preclinical validation, and actionable protocol guidance, while critically situating IWP-2 within the broader scientific and translational landscape.

• Jiedu Xiaozheng Yin Promotes M1 Macrophage Polarization in C

  2026-04-28

  Liu et al. provide compelling evidence that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine, inhibits the progression of colitis-associated colorectal cancer (CAC) by driving macrophage polarization toward a pro-inflammatory M1 phenotype through TLR4-mediated signaling. This work offers mechanistic insight into immunomodulatory anticancer strategies and highlights tools for dissecting relevant pathways.

• Repurposing Lopinavir: Inhibition of MERS-CoV in Cell Cultur

  2026-04-27

  de Wilde et al. conducted a systematic screen of FDA-approved drugs, identifying four small molecules—including Lopinavir (ABT-378)—that inhibit MERS-CoV replication in cell culture at low micromolar concentrations. This work demonstrates the potential for rapid repurposing of antiretroviral agents in the context of emerging viral threats, providing a foundation for further translational antiviral research.

• ALDOB K87 Lactylation Links Mitochondrial Fission to PH Prog

  2026-04-27

  This study uncovers how hypoxia-induced lactylation of aldolase B (ALDOB) at lysine 87 orchestrates mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). The findings highlight a novel lactate–ALDOB–DRP1 axis that drives pathogenic smooth muscle cell proliferation, offering new avenues for targeted research and intervention.

• Maraviroc (UK-427857): Emerging Role in CCR5-Mediated Pathwa

  2026-04-26

  Explore Maraviroc’s advanced utility as a selective CCR5 antagonist for HIV-1 entry inhibition and beyond. This article unveils new mechanistic insights into CCR5's role in inflammation and rheumatoid arthritis, providing a differentiated, evidence-driven perspective for translational researchers.

• Indomethacin as a Molecular Probe: Illuminating Lipid Metabo

  2026-04-25

  Explore indomethacin as a nonsteroidal anti-inflammatory drug and precision molecular probe for dissecting lipid metabolism and membrane signaling. This article offers a unique, in-depth analysis that bridges mechanistic insights with practical assay considerations for inflammation research.

• SB202190 (FHPI): A Potent p38 MAP Kinase Inhibitor for Resea

  2026-04-24

  SB202190 (FHPI) is a highly selective p38 MAP kinase inhibitor with nanomolar potency, widely used in inflammation and cancer therapeutics research. Its ATP-competitive inhibition of p38α and p38β MAPKs enables precise modulation of signal transduction, validated in cellular and animal models.

• Bestatin Stimulates Endothelial Invasion in Fibrin Matrices

  2026-04-24

  This study reveals that bestatin, an aminopeptidase inhibitor, unexpectedly enhances microvascular endothelial cell invasion and capillary-like tube formation in a fibrin matrix, challenging previous assumptions of its solely anti-angiogenic properties. These findings refine our understanding of protease regulation in angiogenesis and highlight the complexity of targeting aminopeptidases in tumor microenvironments.

• BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenes

  2026-04-23

  BFH772 is a selective VEGFR2 inhibitor designed for researchers requiring precise modulation of VEGFR2-mediated angiogenesis, particularly in tumor growth models. It is not suited for workflows needing water-soluble compounds or broad-spectrum kinase inhibition due to its solubility and selectivity properties.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-04-23

  This study demonstrates that pharmacological inhibition of SMYD2, using small-molecule inhibitors such as LLY-507, significantly alleviates cisplatin-induced renal fibrosis and inflammation. The research uncovers SMYD2 as a key epigenetic regulator in chronic kidney disease, broadening the translational potential of SMYD2 inhibitors beyond oncology.

456 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page